Definium Therapeutics reported that its oral LSD-based treatment DT120 reduced symptoms of generalized anxiety disorder in a second successful late-stage study, marking the company's third Phase 3 win this year for the candidate.
Definium Therapeutics announced its experimental LSD-based pill significantly reduced anxiety symptoms in a late-stage study, meeting the trial's main goal. The results mark the company's second major win in two months and sent shares up more than 20% in premarket trading.
Definium Therapeutics reported that a single dose of its LSD-based experimental pill significantly reduced symptoms of major depression in patients in a late-stage trial, sending shares higher. The data brings the drug closer to potential FDA approval.
